The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
Yıl: 2023 Cilt: 4 Sayı: 2 Sayfa Aralığı: 1 - 2 Metin Dili: İngilizce DOI: 10.14744/hf.2022.2022.0044 İndeks Tarihi: 03-06-2023
The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Editoryal Erişim Türü: Erişime Açık
- 1. Kaya E, Yilmaz Y. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative re view with nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab 2022;13:20420188221139650.
- 2. Yilmaz Y, Yilmaz N, Ates F, Karakaya F, Gokcan H, Kaya E, et al. The prevalence of metabolic-associated fatty liver disease in the Turkish popu lation: A multicenter study. Hepatol Forum 2021;2(2):37-42.
- 3. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73(1):202-209.
- 4. Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al; NASH Clinical Research Network (CRN). Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med 2021;385(17):1559-1569.
- 5. Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guide lines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14(6):889-919.
- 6. Yilmaz Y, Zeybel M, Adali G, Cosar AM, Sertesen E, Gokcan H, et al. TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease. Hepatol Forum 2023;(Suppl 1):1-32.
- 7. Jafarov F, Kaya E, Bakir A, Eren F, Yilmaz Y. The diagnostic utility of fibro sis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. Eur J Gastroenterol Hepatol 2020;32(5):642-649.
- 8. Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, et al; US Members of the Global Nash Council. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther 2020;52(3):513-526.
- 9. Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in over weight or obese adults. Clin Gastroenterol Hepatol 2022;20(3):e573-e582.
- 10. 10. Seval GC, Kabacam G, Yakut M, Seven G, Savas B, Elhan A, Cinar K, Idilman R. The natural course of non-alcoholic fatty liver disease. Hepatol Forum 2020;1(1):20-24.
- 11. Oeda S, Takahashi H, Imajo K, Seko Y, Ogawa Y, Moriguchi M, et. al. Ac curacy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in pa tients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol 2020;55(4):428-440.
- 12. Avcu A, Kaya E, Yilmaz Y. Feasibility of fibroscan in assessment of he patic steatosis and fibrosis in obese patients: Report from a general internal medicine clinic. Turk J Gastroenterol 2021;32(5):466-472.
- 13. Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26(2):128-141.
- 14. Salmi A, di Filippo L, Ferrari C, Frara S, Giustina A. Ultrasound and Fi broScan® Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis. Endocrine 2022;78(2):262- 269.
- 15. Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur J Gastroenterol Hepatol 2013;25(11):1330-1334.
- 16. Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019;17(1):156-163.e2.
- 17. Aykut UE, Akyuz U, Yesil A, Eren F, Gerin F, Ergelen R, et al. A compar ison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scand J Gastroenterol 2014;49(11):1343-1348.
- 18. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-re lated HCC: trends, predictions, risk factors and prevention. Nat Rev Gas troenterol Hepatol 2021;18(4):223–238.
- 19. Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in in dividuals with NAFLD using FibroScan-based Agile scores. J Hepatol 2023;78(2):247-259.
- 20. Yilmaz Y, Toraman AE, Alp C, Doğan Z, Keklikkiran C, Stepanova M, et al. Impairment of patient-reported outcomes among patients with non-al coholic fatty liver disease: a registry-based study. Aliment Pharmacol Ther 2023;57(2):215-223.
| APA | Yilmaz Y, Kaya E (2023). The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. , 1 - 2. 10.14744/hf.2022.2022.0044 |
| Chicago | Yilmaz Yusuf,Kaya Eda The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. (2023): 1 - 2. 10.14744/hf.2022.2022.0044 |
| MLA | Yilmaz Yusuf,Kaya Eda The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. , 2023, ss.1 - 2. 10.14744/hf.2022.2022.0044 |
| AMA | Yilmaz Y,Kaya E The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. . 2023; 1 - 2. 10.14744/hf.2022.2022.0044 |
| Vancouver | Yilmaz Y,Kaya E The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. . 2023; 1 - 2. 10.14744/hf.2022.2022.0044 |
| IEEE | Yilmaz Y,Kaya E "The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease." , ss.1 - 2, 2023. 10.14744/hf.2022.2022.0044 |
| ISNAD | Yilmaz, Yusuf - Kaya, Eda. "The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease". (2023), 1-2. https://doi.org/10.14744/hf.2022.2022.0044 |
| APA | Yilmaz Y, Kaya E (2023). The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. Hepatology forum, 4(2), 1 - 2. 10.14744/hf.2022.2022.0044 |
| Chicago | Yilmaz Yusuf,Kaya Eda The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. Hepatology forum 4, no.2 (2023): 1 - 2. 10.14744/hf.2022.2022.0044 |
| MLA | Yilmaz Yusuf,Kaya Eda The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. Hepatology forum, vol.4, no.2, 2023, ss.1 - 2. 10.14744/hf.2022.2022.0044 |
| AMA | Yilmaz Y,Kaya E The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. Hepatology forum. 2023; 4(2): 1 - 2. 10.14744/hf.2022.2022.0044 |
| Vancouver | Yilmaz Y,Kaya E The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. Hepatology forum. 2023; 4(2): 1 - 2. 10.14744/hf.2022.2022.0044 |
| IEEE | Yilmaz Y,Kaya E "The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease." Hepatology forum, 4, ss.1 - 2, 2023. 10.14744/hf.2022.2022.0044 |
| ISNAD | Yilmaz, Yusuf - Kaya, Eda. "The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease". Hepatology forum 4/2 (2023), 1-2. https://doi.org/10.14744/hf.2022.2022.0044 |
